Leading global experts, collaborating with us, develop a variety of educational programmes in the field of hemato-oncology. Explore the latest programmes to support your clinical decision-making.
Programmes in Hemato-oncology
Showing 1 to 6 of 20 results
Update from ASCO 2022 – Myeloma
Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)
Experts
Asst. Prof. Hans Lee-
2 MIN
-
May 2022
Podcast
Episode
3
of 3
Podcast: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics (Episode 3 of 3)
The third episode in the series, Dr. María Victoria Mateos and Dr. Alexander Lesokhin discuss how they choose the best treatment regimen for patients with multiple myeloma and a high-risk cytogenetic profile
Experts
Assoc. Prof. María Victoria Mateos, Dr Alexander M Lesokhin-
Downloadable
Resources -
20 MIN
-
Mar 2022
Lymphoma Update from ASH 2021
Dr. Matthew J. Matasar summarises the highlights in lymphoma from ASH 2021, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL
Experts
Dr Matthew J. Matasar-
Downloadable
Resources -
5 MIN
-
Dec 2021
Publication
DLBCL Review Paper Published in The Oncologist
Authored by LYMPHOMA & MYELOMA CONNECT members, the paper ‘Translating the Biology of Diffuse Large B-cell Lymphoma into Treatment’ provides an overview of recent advances in DLBCL biology and how they can be translated into clinical care.
Experts
Dr Matthew J. Matasar, Dr Massimo Magagnoli, Prof. Alexey V Danilov-
Downloadable
Resources -
5 MIN
-
Nov 2021
Conference update
Update from the 2021 Autumn Congresses in Multiple Myeloma
Dr Claudio Cerchione summarises highlights from SOHO, SOHO Italy and IMW 2021
Experts
Dr Claudio Cerchione-
Downloadable
Resources -
10 MIN
-
Nov 2021
Podcast
Episode
2
of 3
Podcast: Choosing the Best Treatment Regimen in RRMM (Episode 2 of 3)
In this second episode, Dr. Joshua Richter and Dr. Karthik Ramasamy discuss their views on choosing the best treatment regimen in relapsed/refractory multiple myeloma (RRMM)
Experts
Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter-
Downloadable
Resources -
25 MIN
-
Oct 2021
